Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) play a regulatory roles in metabolism across several tissues and have potential value in the treatment of MASLD. A novel umbrella review was conducted to assess the efficacy and safety of GLP-1 RAs in MASLD in multiple dimensions. Following the PRISMA 2020 guidance, five databases were searched from inception to 30 September, 2025. The quality of the included systematic reviews was assessed using AMSTAR 2. Twenty-three meta-analyses and systematic reviews were included. All outcomes regarding the efficacy of GLP-1 RAs in MASLD were summarized into five categories: liver characteristics, liver enzyme levels, anthropometric measurements, metabolic markers, and inflammatory markers. GLP-1 RAs show potential benefits in improving MASLD across multiple dimensions with a relatively acceptable safety profile, but nearly 80% of included reviews are of critically low quality with high evidence overlap. Thus, our findings are preliminary and hypothesis-generating. High-quality studies are urgently needed.
Wu et al. (Thu,) studied this question.